1-Acylglycerol-3-Phosphate O-Acyltransferase 2 (Lysophosphatidic Acid Acyltransferase, Beta) (AGPAT2) Peptide
-
- Target See all AGPAT2 products
- AGPAT2 (1-Acylglycerol-3-Phosphate O-Acyltransferase 2 (Lysophosphatidic Acid Acyltransferase, Beta) (AGPAT2))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- LEAIPTSGLT AADVPALVDT CHRAMRTTFL HISKTPQENG ATAGSGVQPA
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of AGPAT2 antibody,
Alternative Names: AGPAT2 control peptide, AGPAT2 antibody Blocking Peptide, Anti-AGPAT2 Blocking Peptide, 1-Acylglycerol-3-Phosphate O-Acyltransferase 2 Blocking Peptide, ,1-AGPAT2 Blocking Peptide, BSCL Blocking Peptide, BSCL1 Blocking Peptide, LPAAB Blocking Peptide, LPAAT-beta Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- AGPAT2 (1-Acylglycerol-3-Phosphate O-Acyltransferase 2 (Lysophosphatidic Acid Acyltransferase, Beta) (AGPAT2))
- Background
- AGPAT2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance.
- Molecular Weight
- 27 kDa
-